Fresenius SE & Co. (OTCMKTS:FSNUY) Stock Short Interest Report for October

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 367,297 shares, an increase of 1,170.7% from the September 30th total of 28,906 shares. Based on an average daily volume of 1,015,424 shares, the short-interest ratio is presently 0.4 days. Currently, 0.0% of the company’s shares are short sold.

Fresenius SE & Co. Trading Up 0.9%

Shares of OTCMKTS:FSNUY traded up $0.11 on Monday, hitting $12.99. 97,381 shares of the company’s stock were exchanged, compared to its average volume of 170,762. Fresenius SE & Co. has a 12 month low of $10.33 and a 12 month high of $33.93. The stock has a market capitalization of $29.27 billion, a price-to-earnings ratio of 16.44 and a beta of 0.60. The business’s 50 day simple moving average is $12.95 and its two-hundred day simple moving average is $12.91. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.91 billion for the quarter, compared to analysts’ expectations of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. Analysts anticipate that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on FSNUY. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Fresenius SE & Co. currently has an average rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.